Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Total Current Liabilities: 2023-2025

Historic Total Current Liabilities for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to $15.5 million.

  • BioLineRx's Total Current Liabilities fell 49.28% to $15.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $15.5 million, marking a year-over-year decrease of 49.28%. This contributed to the annual value of $15.4 million for FY2024, which is 63.99% down from last year.
  • As of Q2 2025, BioLineRx's Total Current Liabilities stood at $15.5 million, which was up 10.33% from $14.0 million recorded in Q1 2025.
  • Over the past 5 years, BioLineRx's Total Current Liabilities peaked at $42.8 million during Q4 2023, and registered a low of $12.0 million during Q1 2023.
  • Moreover, its 3-year median value for Total Current Liabilities was $15.4 million (2024), whereas its average is $21.4 million.
  • Data for BioLineRx's Total Current Liabilities shows a peak YoY increase of 160.55% (in 2024) and a maximum YoY decrease of 63.99% (in 2024) over the last 5 years.
  • BioLineRx's Total Current Liabilities (Quarterly) stood at $42.8 million in 2023, then tumbled by 63.99% to $15.4 million in 2024, then plummeted by 49.28% to $15.5 million in 2025.
  • Its last three reported values are $15.5 million in Q2 2025, $14.0 million for Q1 2025, and $15.4 million during Q4 2024.